Fig 2. Head to head comparison of kinase inhibitors against Pa-induced IL-6 and CXCL8 release, and cell viability.
BEAS-2B cells underwent a two-hour pre-treatment with kinase inhibitors at a single concentration known to completely inhibit the target kinase enzyme activity. The cells were stimulated with Pa at 2.5 x 107 CFU/ml for one hour followed by addition of gentamicin at 100 μg/ml and a further four-hour incubation. The concentration of (A) IL-6 and (B) CXCL8 in the cell-free supernatant was measured by sandwich ELISA. (C) BEAS-2B cell viability was measured after compound treatment and Pa infection, using an MTT assay; cell viability was compared to cells treated with DMSO and Pa. Friedman test with Dunn’s multiple comparisons was used to compare each kinase inhibitor with vehicle treatment. n = 6, showing median with IQR (* = p<0.05, ** = p<0.01 and *** = p<0.001). Compound concentrations: SB203580–3.8 μg/ml; BIRB796–0.5 μg/ml; SP600125–2.2 μg/ml; PD98059–8.0 μg/ml; BAY 61–3606–0.5 μg/ml and Dasatinib– 0.1 μg/ml.